Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Study Sponsor

Eli Lilly and Company (Chorus, a division of Lilly Research Laboratories)

Clinical Trial Registry ID


Study details and eligibility criteria can be found at the following Clinical Trial Registry Link:

Contacts and Locations

To learn more about this study and find a study site near you please visit or call toll free (877.605.7546).

Study Site Locations

United States, Florida
Forward Clinical Trials, Inc
Tampa, Florida, US 33624

United States, Illinois
Northwestern University
Chicago, Illinois, US 60611

United States, New York
Icahn School of Medicine
New York, New York, US 10029

United States, Oregon
Oregon Health and Science University
Portland, Oregon, US 97239

United States, Texas
Menter Dermatology Research Institute
Dallas, Texas, US 75246

Center for Clinical Studies
Houston, Texas, US 77004
Webster, Texas, US 77598